Randel Richner is the founder of Neocure Group, a consulting firm with offices located in Boston, Washington D.C. and California. She served as Vice President, Global Government Affairs for Boston Scientific Corporation (BSC) from 1997 until June, 2006. At Boston Scientific, Richner built a global reimbursement and outcomes strategic process for new and existing less invasive medical technologies for BSC product platforms. She was actively engaged in national and international policy and legislative arenas as an advocate for the benefits of innovative medical technology, FDA, regulatory, international trade and payment issues.

Richner served a four-year term as the first industry representative to the Executive Committee of the Medicare Coverage Advisory Committee (MCAC), contributing to the development of national coverage and MCAC process guidelines. In 2007, she was reappointed to MedCAC (renamed) for a 2-year term. She is a frequent contributor on policy panels on health care issues related to the technology industry, such as an Institute of Medicine (IOM) special committee on cost-effectiveness and post-market surveillance in 2005. She was recently elected to the MassMEDIC Board of Directors; a Fellow in the College of Fellows of the American Institute of Medical and Biological Engineers (AIMBE), a National Institutes of Health Commercialization Program (NIH-CAP) advisor; Executive Advisory Board to the Dean of the University of Michigan’s School of Public Health and the University of Michigan Ross Business School Healthcare Life Sciences Advisory Board.  Richner also recently completed a 3 year appointment to the Executive Advisory Board of the Center for Evaluation of Value and Risk in Health (CEVRH) Tufts New England Medical Center, and former Independent Board Observer of Entellus Medical.

Prior to BSC, Richner was a Director of Outcomes Research and Pharmacoeconomics at GlaxoSmithKline (formerly SmithKline Beecham) in both London, England and Philadelphia, focusing primarily on global pricing and economic issues for cardiopulmonary and diabetic drugs in development. She was a member of the Global Health Policy Group (GHPG) consortium of leaders of health economics groups in the pharmaceutical and device industry. Richner has been an active member of the International Society of Pharmacoeconomics and Research (ISPOR), and founder of the U.S. Medical Device Council of ISPOR, Asia-Pacific Medical Device Council.

Richner holds a Master’s Degree in Public Health Policy and Administration and a Bachelor of Science in Nursing, magna cum laude, from the University of Michigan. Before her career in health economics and policy, she was a practicing dialysis and transplant nurse for 13 years at the University of Michigan Hospital and Northern Michigan Hospital.

For an abbreviated list of Neocure staff publications please click here.